BASILICO, Annacristina
 Distribuzione geografica
Continente #
NA - Nord America 649
EU - Europa 289
AS - Asia 125
AF - Africa 2
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.068
Nazione #
US - Stati Uniti d'America 647
CN - Cina 80
IE - Irlanda 62
SE - Svezia 54
IT - Italia 53
UA - Ucraina 30
FR - Francia 23
DE - Germania 17
FI - Finlandia 17
KR - Corea 15
GB - Regno Unito 13
VN - Vietnam 11
SG - Singapore 10
BE - Belgio 8
JP - Giappone 5
NL - Olanda 3
CA - Canada 2
ES - Italia 2
HU - Ungheria 2
PK - Pakistan 2
SN - Senegal 2
AT - Austria 1
AU - Australia 1
CZ - Repubblica Ceca 1
EU - Europa 1
GR - Grecia 1
HK - Hong Kong 1
HR - Croazia 1
NZ - Nuova Zelanda 1
RO - Romania 1
TR - Turchia 1
Totale 1.068
Città #
Chandler 111
Ann Arbor 87
Dublin 62
Beijing 54
Dearborn 28
Fairfield 26
Houston 22
Nyköping 20
Medford 18
Jacksonville 17
Torino 16
Princeton 15
Woodbridge 13
Villeurbanne 12
Dong Ket 11
Cambridge 10
Seattle 10
Wilmington 10
Boston 9
Turin 9
Ashburn 8
Brussels 8
San Diego 6
Boardman 5
Edinburgh 4
Hangzhou 4
Hefei 4
New York 4
Redwood City 4
Tokyo 4
Amsterdam 3
Singapore 3
Buffalo 2
Madrid 2
Milan 2
Mountain View 2
Nepi 2
Rende 2
Serio 2
Silver Spring 2
Upper Marlboro 2
Verona 2
Zhengzhou 2
Amiens 1
Anaheim 1
Andover 1
Atlanta 1
Auckland 1
Baltimore 1
Bologna 1
Budapest 1
Cagliari 1
Changsha 1
Düsseldorf 1
Fremont 1
Glen Mills 1
Guangzhou 1
Helsinki 1
Istanbul 1
Kunming 1
London 1
Los Angeles 1
Montreal 1
Nanchang 1
Nanjing 1
Nanning 1
Norwalk 1
Ottawa 1
Pakistan 1
Palermo 1
Paris 1
Philadelphia 1
Ponzano 1
Port Lavaca 1
Reutlingen 1
San Mateo 1
Seoul 1
Shanghai 1
Shenyang 1
Troy 1
Vienna 1
Villadose 1
Voulangis 1
Wuhan 1
Xian 1
Zagreb 1
Totale 682
Nome #
Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth 123
MET/HGF co-targeting in pancreatic cancer: A tool to provide insight into the tumor/stroma crosstalk 122
"Active" cancer immunotherapy by anti-Met antibody gene transfer 101
Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-“decoy” strategy 95
Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. 92
A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met 82
An HGF-MSP chimera disassociates the trophic properties of scatter factors from their pro-invasive activity. 69
An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice 62
Molecular engineering strategies tailoring the apoptotic response to a met therapeutic antibody 61
Magic-factor 1, a partial agonist of Met, induces muscle hypertrophy by protecting myogenic progenitors from apoptosis 60
Targeting the tumor and its microenvironment by a dual-function decoy Met receptor 58
hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers 52
Engineering, Characterization, and Biological Evaluation of an Antibody Targeting the HGF Receptor 50
Hgf/met axis induces tumor secretion of tenascin-c and promotes stromal rewiring in pancreatic cancer 43
A receptor-antibody hybrid hampering MET-driven metastatic spread 30
Totale 1.100
Categoria #
all - tutte 3.560
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.560


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20195 0 0 0 0 0 0 0 0 0 1 4 0
2019/2020146 2 0 6 10 17 25 22 16 16 16 11 5
2020/2021139 6 6 8 6 15 9 14 7 13 11 10 34
2021/2022266 17 16 12 20 8 18 6 7 12 11 106 33
2022/2023322 23 28 10 26 24 76 20 31 48 2 27 7
2023/202480 17 19 6 3 6 16 1 3 1 8 0 0
Totale 1.100